EUCTR2005-001074-27-GB进行中（未招募）1 期
A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING DOSE, CLINICAL TRIAL OF INTRA-VENOUS MICROPLASMIN ADMINISTRATION IN PATIENTS WITH ACUTE ISCHEMIC STROKE - MITI-IV
ThromboGenics Ltd.0 个研究点目标入组 40 人开始时间: 2012年2月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Acute ischemic stroke (defined as a measurable neurological deficit of sudden onset considered secondary to focal cerebral ischemia and not otherwise attributable to ICH or other condition), with onset within 12 hours before randomization (Onset is defined as the time the patient was last seen in a normal state, or bedtime for unwitnessed strokes occurring during the night).
- •2. Evidence of a perfusion defect of at least 2 cm in diameter, as assessed by MRI (PWI), corresponding to the acute stroke syndrome. The PWI will be assessed by relative mean transit time (MTT) images.
- •3. Ability to initiate study drug administration within 1 hour of completion of MRI and within 12 hours of stroke onset.
- •4. Male or female age 18-85 (inclusive)
- •5. Patients with baseline NIHSS > 6 and < 22
- •6. Prior to inclusion in the study and following a full explanation of the nature and purpose of the study, the patient or the patient’s legal representative must consent/assent to participate by signing the Informed Consent document.
- •7. Women of child-bearing potential must have a negative pregnancy test prior to enrolment and be using a reliable form of contraception
- •8. Patients must be ambulatory prior to stroke onset.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •General exclusion criteria
- •1. Participation in another study with an investigational drug or device within the previous 30 days, prior participation in the present study, or planned participation in another trial within the timeframe of the current trial
- •2. Symptoms suggestive of subarachnoid hemorrhage, even if CT scan or MRI is negative for hemorrhage
- •3. Women known to be pregnant, lactating, or having a positive or indeterminate pregnancy test
- •Stroke related exclusion criteria
- •4. Neurological deficit that has led to stupor or coma (NIHSS Level Of Consciousness Item 1a score >or=2)
- •5. High clinical suspicion of septic embolus
- •6. Thrombosis involving cerebral veins
- •7. Rapidly improving neurological signs at any time before initiation of study drug administration
- •Imaging related exclusion criteria
- •8. Hemorrhagic transformation or intracerebral hemorrhage observed on baseline CT of the brain or gradient recalled echo (GRE) magnetic resonance imaging
- •9. CT or MRI evidence of nonvascular cause for the neurological symptoms
- •10. Ischemic lesion consistent with lacunar stroke
- •11. PWI not obtained or uninterpretable
- •12. No MTT defect corresponding to acute stroke deficit
- •13. Large hypodensity on CT involving > 1/3 of the MCA territory
- •14. Baseline DWI volume > 1/3 of the MCA territory
- •15. Signs of mass effect causing shift of midline structures on CT or MRI
- •16. Unable to undergo MRI (i.e., ferrous implants, cardiac pacemakers, agitation, claustrophobia or known sensitivity to MRI contrast agents)
- •Safety related exclusion criteria
- •17. Congenital or acquired coagulopathy causing either of the following
- •a. activated partial thromboplastin time prolongation greater than 2 seconds above
- •the ULN for local laboratory
- •b. International normalized ratio of 1.4 or more.
- •18. Uncontrolled hypertension defined as a systolic blood pressure > 180 mm Hg or a diastolic blood pressure > 100 mm Hg on 3 separate occasions at least 10 minutes apart or requiring continuous IV therapy.
- •19. History of stroke within the previous 3 months
- •20. Seizures at any time between stroke onset to planned initiation of study drug
- •21. History of intracranial hemorrhage
- •22. History of surgery, lumbar puncture, biopsy or trauma to internal organs within the previous 30 days.
- •23. Major trauma at the time of stroke
- •24. Head trauma within the previous 90 days.
- •25. Known bleeding diathesis.
- •26. Baseline platelet count < 100 X 109/L.
- •27. Blood glucose > 400mg/dl or <50 mg/dl if administration of glucose does not rapidly reverse neurological deficit
- •Exclusion criteria that may potentially interfere with outcome assessment
- •28. Life expectancy <3 months
- •29. Other serious illness that in the opinion of the investigator may confound clinical assessment (e.g. hepatic, cardiac, or renal failure, advanced cancer)
- •Exclusion criteria related to concomitant medication
- •30. If treatm
研究者
相似试验
已完成
不适用
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED,PARALLEL-GROUP PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OFMASITINIB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE-G30G30PER-037-16AB Science,1
进行中（未招募）
1 期
A clinical study to determine the efficacy and tolerability of two doses of AllerT for reducing allergy symptoms for patients with Birch allergy.Adult patients, 18-65 years of age, suffering from moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the two preceding birch pollen seasons.MedDRA version: 19.1Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870EUCTR2016-000076-23-SKANERGIS SA450
进行中（未招募）
1 期
A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ASSESS THE EFFICACY AND TOLERABILITY OF TWO DOSING REGIMENS OF ALLERT, IN ADULTS WITH BIRCH POLLEN ALLERGIC RHINITIS/RHINOCONJUNCTIVITISAdult patients, 18-65 years of age, suffering from moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the two preceding birch pollen seasons.MedDRA version: 19.0Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870EUCTR2016-000076-23-FIANERGIS SA450
进行中（未招募）
1 期
A clinical study to determine the efficacy and tolerability of two doses of AllerT for reducing allergy symptoms for patients with Birch allergy.Adult patients, 18-65 years of age, suffering from moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the two preceding birch pollen seasons.MedDRA version: 19.0Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870EUCTR2016-000076-23-LTANERGIS SA450
进行中（未招募）
1 期
A clinical study to determine the efficacy and tolerability of two doses of AllerT for reducing allergy symptoms for patients with Birch allergy.Adult patients, 18-65 years of age, suffering from moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the two preceding birch pollen seasons.MedDRA version: 20.0Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000023864EUCTR2016-000076-23-DEANERGIS SA450